Dataset from A Randomised, Double-blind, Double-dummy, Crossover Efficacy and Safety Comparison of 4-week Treatment Periods of Ba 679 BR Respimat® 5 μg and Tiotropium Inhalation Capsule 18 μg in Patients With COPD

The objective of this trial is to compare the efficacy and the safety of Ba 679 BR Respimat 5 ug once daily to tiotropium inhalation capsule 18 ug (Spiriva inhalation capsule) in a crossover study of 4-week treatment periods in patients with COPD.

本临床试验的目的为，在针对慢性阻塞性肺疾病（Chronic Obstructive Pulmonary Disease, COPD）患者开展的、采用4周治疗周期的交叉设计临床试验中，对比每日一次给药的Ba 679 BR Respimat 5 μg制剂与噻托溴铵吸入胶囊18 μg（思力华吸入胶囊，Spiriva inhalation capsule）的疗效与安全性。